Virbac : revenue grew by +5.5% at constant exchange rates at the end of September 2018

11.10.18 17:50
Virbac : revenue grew by +5.5% at constant exchange rates at the end of September 2018

Revenue grew by +5.5% at constant exchange rates at the end of September 2018


Year-to-date September 2018


€634.3 million



Growth at

constant exchange rates


Growth at constant exchange rates and scope 1


+5.5% of which

companion animals +8.4% (+7.4% outside of the USA)

food producing animals +2.6%

1 Growth at constant exchange rates and scope is the organic growth of sales, excluding the impact of exchange rate changes, by calculating the indicator for the financial year in question and that for the previous financial year on the basis of identical exchange rates (the exchange rate used is that in effect for the previous financial year), and excluding the impact of changes in scope, by calculating the indicator for the financial year in question on the basis of the scope of consolidation for the previous financial year.

Quarterly consolidated revenue

Group revenue reached €204.3 million in the third quarter, an increase of +6.1% at real rates when compared to the same period in 2017. At comparable exchange rates, third-quarter revenue saw faster growth than in the first half, showing sustained growth of +9.3%. The quarter's growth is mainly driven by activity in the United States, which is enjoying a favorable base effect compared to the same period in 2017. It should be noted that ex-distributor sales in the United States of Virbac products to veterinary clinics are growing overall by +14%, with Sentinel and Iverhart posting growth of +7% and +45% respectively, compared to 2017. Latin America exclusive of Chile, driven by double-digit growth in Brazil and Mexico, and with Asia Pacific buoyed by China, New Zealand and Australia, contribute positively to growth, offsetting a stable Europe and declining Chile. In terms of species, growth originates primarily from the companion animal segment, with products such as parasiticides, petfood, vaccines and dermatology ranges. Furthermore, products for cattle, such as vaccines and food supplements, play a role in the quarter's performance.

Cumulative revenue at the end of September

Revenue reached €634.3 million versus €630.2 million over the same period in 2017, recording total growth of +0.7%. Excluding the negative effect of exchange rates, notably the Indian rupee, the American and Australian dollar, and the Brazilian real, revenue is growing at +5.5%.

In the United States, activity grew by +6.4% at real rates, including +13.8% at comparable exchange rates, steadily improving since the beginning of the year. This performance is due to large sales of Sentinel in the third quarter, as well as by sustained performance in dental ranges and specialty products. It should be noted that ex-distributor sales in the United States of Virbac products to veterinary clinics are growing well at +6% at the end of September. Although Sentinel is now at just -1%, Iverhart ranges continue growing at +30%, and all other ranges post average growth of +19% at the end of September 2018.

Outside of the United States, the Group is stable at real rates at the end of September, however, organic growth remains strong at +4.5%. Europe shows growth of +2.5% at real rates, including+3.0% at constant rates, due to a good contribution by France, the United Kingdom, and Germany in particular, offsetting difficulties encountered in Southern Europe (competition facing the vaccine against canine leishmaniosis and declining antibiotic sales in Spain). In the rest of the world, the Asia-Pacific area shows a change of -1.9%, including +6% at constant exchange rates (+7.8% excluding an unfavorable base effect related to licensing revenue recognized in 2017), mainly due to momentum in India, New Zealand and Australia. Growth in Latin America, exclusive of Chile, amounted to +1.6% at real rates and +13.5% at constant rates, driven by activity in Brazil and Mexico. Lastly, Chile shows a decline of -11.5% at real rates, including -6.4% at constant rates, due in particular to weaker antibiotic and oral vaccine sales compared to the same period in 2017.

In terms of species, revenue in the companion animal segment is rising overall by +4.6%, including +8.4% at constant exchange rates. The ranges showing the most significant growth are the specialty ranges (especially Zoletil and Suprelorin), petfood, and the dental range, which offset the decline in parasiticide ranges.

In the food producing animal segment, total change amounted to -3.6%, including +2.6% at constant exchange rates. Performance varies at constant rates, with the bovine sector growing at +8.1%, buoyed by nutritional products and ruminant vaccines, while industrial (swine and poultry) and aquaculture show respective declines of -3.8% and -14.8%, related to weaker sales of antibiotics and oral vaccines for salmon.


The Group anticipates growth in revenue at constant rates that should show a low single-digit increase in 2018 compared to 2017, and a current opeRating profit, before depreciation of assets arising from acquisitions ratio on revenue at constant exchange rates with growth at around 1 point at constant exchange rates compared to 2017.

Debt relief should be around €30 million for the year at constant exchange rates. Furthermore, the Group obtained a relaxation of its financial agreement (net debt/Ebitda) with its bankers for 2018. Thus, it is at 5.0 at the end of June, 2018, and at 4.25 at the end of December, 2018. The Group's financing is ensured primarily through an RCF (Revolving credit facility) line of 420 million euros, maturing in 2022, as well as bilateral bank loans, financing by the European Investment Bank (EIB) and Schuldschein disintermediated contracts, whose terms are between four and ten years.


Unaudited - in million euros
2018 2017 Evolution Evolution

at constant exchange rates

at constant exchange rates and scope 1
1st quarter revenue 193.5 199.7 -3.1% +3.3% +3.3%
2nd quarter revenue 236.5 237.8 -0.6% +4.4% +4.4%
3rd quarter revenue 204.3 192.7 +6.1% +9.3% +9.3%
Revenue at the end of September 634.3 630.2 +0.7% +5.5% +5.5%

Focusing on animal health from the beginning

Virbac offers veterinarians, farmers and pet owners in more than 100 countries a comprehensive and practical range of products and services. With these innovative solutions covering the majority of animal species and diseases, Virbac contributes day after day to shape the future of animal health.

Virbac: revenue grew by +5.5% at constant exch. rates

This announcement is distributed by West Corporation on behalf of West Corporation clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Virbac via Globenewswire


Breaking News

Kurs- und weitere Informationen zum Thema:


Aktuelle Diskussionen zum Thema:

Aktuelle Nachrichten zum Unternehmen:

Alle Nachrichten zum Unternehmen

Aktuelle Analysen zu den Unternehmen:

Weitere Meldungen
15.10 SeaBird Exploration: SeaBird.
15.10 Klövern AB (publ): Klövern .
13.10 Ad hoc: CECONOMY AG: P.
12.10 WISeKey Leverages its Cer.
12.10 Maurel & Prom: confirms it .
12.10 INVENTIVA to Participate i.
12.10 SeaBird Exploration: SeaBird.
12.10 Ad hoc: ad pepper media In.
12.10 Ad hoc: niiio finance group .
12.10 Ad hoc: Sino-German United.
12.10 Ad hoc: UMS United Medica.
12.10 TGS and Schlumberger Ann.
12.10 Incap to increase its estimat.
11.10 Eckert & Ziegler BEBIG SA.
11.10 Ad hoc: cyan AG: Durchfüh.
11.10 Ad hoc: BB Biotech AG rap.
11.10 Virbac : revenue grew by +.
11.10 Ad hoc: HWA AG soll neu.
11.10 Net Insight's Nomination Com.
11.10 Prosafe SE: Safe Zephyrus .
11.10 Ad hoc: Deutsche Industrie .
11.10 Ad hoc: DEAG Deutsche En.
11.10 Ethan Allen Comments on B.
11.10 Amer Sports Response to M.
11.10 Ad hoc: Heidelberg Pharma .
11.10 Ad hoc: LPKF erhöht Umsa.
11.10 Radisson Hospitality AB's Q.
11.10 Ad hoc: TTL Beteiligungs- u.
11.10 INGENICO GROUP: Commun.
11.10 Ad hoc: ISRA VISION AG: .

Welche Social Networks nutzen Sie meistens?
Linked in

Stimmen: 61855 , Ergebnis

Status: nicht eingeloggt

Registrieren | Passwort vergessen?
Im Bereich Nachrichten:
Adidas: Da ist das Kaufsignal!
Experte: Stefan Hofmann, STOCK-WORLD
Öl und Gold: Das sind jetzt ...
Claus Vogt, (14:23)
Experte: Claus Vogt,
Darauf sollten Deutsche ...
Volker Gelfarth, (12:12)
Experte: Volker Gelfarth,
Hat der Bitcoin Kurs seinen ...
Stefan Hofmann, Stock-World (11:34)
Experte: Stefan Hofmann, Stock-World
Börse Stuttgart AG, (11:31)
Experte: Börse Stuttgart AG,
Dieses Mal rettet die Fed ...
Sven Weisenhaus, Stockstreet GmbH (10:54)
Experte: Sven Weisenhaus, Stockstreet GmbH
Jörg Schulte, JS-Research (10:50)
Experte: Jörg Schulte, JS-Research
Tourismus: Warum wir eine ...
Stock-World Redaktion, STOCK-WORLD (10:43)
Experte: Stock-World Redaktion, STOCK-WORLD
Europa braucht einen ...
Frank Schäffler, (10:34)
Experte: Frank Schäffler,
BioNTech Aktie: Bullen ...
Robert Sasse, (10:26)
Experte: Robert Sasse,
Wochenausblick: Börsen ...
HypoVereinsbank onema., (09:21)
Experte: HypoVereinsbank onemarkets,
Lasst doch jeden selbst ...
Bernd Niquet, Autor (09:08)
Experte: Bernd Niquet, Autor
Deutsche Börse-Discounter ...
Walter Kozubek, (08:08)
Experte: Walter Kozubek,
Niquet's World
Neues vom Portal
Hat der Bitcoin Kurs seinen Boden gefunden?
Letzte Börsen-Meldung
Letzte Börsen-Analyse
Top-Klicks News
Top-Klicks Analysen